Histone Modifications in Cancer Biology and Prognosis

  • Siavash K. KurdistaniEmail author
Part of the Progress in Drug Research book series (PDR, volume 67)


Cancer is a disease of genome sequence alterations as well as epigenetic changes. Epigenetics refers in part to the mechanisms by which histones affect various DNA-based processes, such as gene regulation. Histones are proteins around which the DNA wraps itself to form chromatin – the physiologically relevant form of the human genome. Histones are modified extensively by posttranslational modifications that alter chromatin structure and serve to recruit to or exclude protein complexes from DNA. Aberrations in histone modifications occur frequently in cancer including changes in their levels and distribution at gene promoters, gene coding regions, repetitive DNA sequences, and other genomic elements. Locus-specific alterations in histone modifications may have adverse effects on expression of nearby genes but so far have not been shown to have clinical utility. Cancer cells also exhibit alterations in global levels of specific histone modifications, generating an additional layer of epigenetic heterogeneity at the cellular level in tumor tissues. Unlike locus-specific changes, the cellular epigenetic heterogeneity can be used to define previously unrecognized subsets of cancer patients with distinct clinical outcomes. In general, increased prevalence of cells with lower global levels of histone modifications is prognostic of poorer clinical outcome such as increased risk of tumor recurrence and/or decreased survival probability. Prognostic utility of histone modifications has been demonstrated independently for multiple cancers including those of prostate, lung, kidney, breast, ovary, and pancreas, suggesting a fundamental association between global histone modification levels and tumor aggressiveness, regardless of cancer tissue of origin. Cellular levels of histone modifications may also predict response to certain chemotherapeutic agents, serving as predictive biomarkers that could inform clinical decisions on choice and course of therapy. The challenge before us is to understand how global levels of histone modifications are established and maintained and what their mechanistic links are to the cancer clinical behavior.


Human Papilloma Virus Histone Modification Histone Acetylation H3K9me2 Level Histone Modify Enzyme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



S.K.K. is funded by the Howard Hughes Medical Institute (early career award), the California Institute for Regenerative Medicine (new faculty award) and the American Cancer Society.


  1. 1.
    Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148–1159PubMedCrossRefGoogle Scholar
  2. 2.
    Gal-Yam EN, Saito Y, Egger G, Jones PA (2008) Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 59:267–280PubMedCrossRefGoogle Scholar
  3. 3.
    American Association for Cancer Research Human Epigenome Task Force; European Union, Network of Excellence, Scientific Advisory Board (2008) Moving AHEAD with an international human epigenome project. Nature 454:711–715Google Scholar
  4. 4.
    Ptashne M (2007) On the use of the word ‘epigenetic’. Curr Biol 17:R233–R236PubMedCrossRefGoogle Scholar
  5. 5.
    Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451:147–152PubMedCrossRefGoogle Scholar
  6. 6.
    Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137:1032–1046PubMedCrossRefGoogle Scholar
  7. 7.
    Madhani HD, Francis NJ, Kingston RE, Kornberg RD, Moazed D, Narlikar GJ, Panning B, Struhl K (2008) Epigenomics: a roadmap, but to where? Science 322:43–44PubMedCrossRefGoogle Scholar
  8. 8.
    Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom WS, Okano H, Ko MS, Ohlsson R, Longo DL, Feinberg AP (2005) Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307:1976–1978PubMedCrossRefGoogle Scholar
  9. 9.
    Berk AJ (2005) Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24:7673–7685PubMedCrossRefGoogle Scholar
  10. 10.
    DeCaprio JA (2009) How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40. Virology 384:274–284PubMedCrossRefGoogle Scholar
  11. 11.
    Ferrari R, Berk AJ, Kurdistani SK (2009) Viral manipulation of the host epigenome for oncogenic transformation. Nat Rev Genet 10:290–294PubMedCrossRefGoogle Scholar
  12. 12.
    Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM et al (2000) Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24:300–303PubMedCrossRefGoogle Scholar
  13. 13.
    Giles RH, Peters DJ, Breuning MH (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14:178–183PubMedCrossRefGoogle Scholar
  14. 14.
    Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ (2008) Adenovirus small e1a alters global patterns of histone modification. Science 321:1084–1085PubMedCrossRefGoogle Scholar
  15. 15.
    Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK (2008) Epigenetic reprogramming by adenovirus e1a. Science 321:1086–1088PubMedCrossRefGoogle Scholar
  16. 16.
    Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRefGoogle Scholar
  17. 17.
    Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5:845–856PubMedCrossRefGoogle Scholar
  18. 18.
    Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262–1266PubMedCrossRefGoogle Scholar
  19. 19.
    Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK (2009) Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 174:1619–1628PubMedCrossRefGoogle Scholar
  20. 20.
    Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA et al (2009) Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69:3802–3809PubMedCrossRefGoogle Scholar
  21. 21.
    Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Hines OJ, Reber H, Seligson DB, Horvath S, Kurdistani SK et al (2009) Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 28(8):1358–1365Google Scholar
  22. 22.
    Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB et al (2008) Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47:701–706PubMedCrossRefGoogle Scholar
  23. 23.
    Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I, Walter B, Hofstadter F, Buttner R, Muller SC et al (2010) Global levels of histone modifications predict prostate cancer recurrence. Prostate 70(1):61–69PubMedCrossRefGoogle Scholar
  24. 24.
    Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA, Rodriguez JA (2007) Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 25:4358–4364PubMedCrossRefGoogle Scholar
  25. 25.
    Van Den Broeck A, Brambilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, Eymin B, Khochbin S, Gazzeri S (2008) Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 14:7237–7245CrossRefGoogle Scholar
  26. 26.
    Tzao C, Tung HJ, Jin JS, Sun GH, Hsu HS, Chen BH, Yu CP, Lee SC (2009) Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol 22:252–260PubMedCrossRefGoogle Scholar
  27. 27.
    Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391–400PubMedCrossRefGoogle Scholar
  28. 28.
    Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ (2008) The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 15:1968–1976PubMedCrossRefGoogle Scholar
  29. 29.
    Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C (2006) Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 70:366–377PubMedCrossRefGoogle Scholar
  30. 30.
    Lee JH, Park JH, Jung Y, Kim JH, Jong HS, Kim TY, Bang YJ (2006) Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 5:3085–3095PubMedCrossRefGoogle Scholar
  31. 31.
    Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M, Ritchie JW (2007) The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 60:275–283PubMedCrossRefGoogle Scholar
  32. 32.
    Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51PubMedCrossRefGoogle Scholar
  33. 33.
    Weichert W (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280:168–176PubMedCrossRefGoogle Scholar
  34. 34.
    Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES (2009) Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 15:3163–3171PubMedCrossRefGoogle Scholar
  35. 35.
    Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB (2009) ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324:1076–1080PubMedCrossRefGoogle Scholar
  36. 36.
    Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033PubMedCrossRefGoogle Scholar
  37. 37.
    Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR, Issa JP (2008) Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One 3:e2037PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2011

Authors and Affiliations

  1. 1.Departments of Biological Chemistry and Pathology and Laboratory MedicineEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, David Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations